Atypical Ductal Hyperplasia: What the Diagnosis Means and What Comes Next

A diagnosis of “atypical ductal hyperplasia” often leaves patients with unanswered questions. It is not cancer, but it is not negligible either.

Bedford Breast Center, in Beverly Hills, CA, evaluates and manages ADH diagnoses for patients across Los Angeles and nationwide.

What is Atypical Ductal Hyperplasia?

The breast ducts are lined with cells that, under normal conditions, grow in a predictable, organized pattern. Ductal hyperplasia means those cells have multiplied more than expected. ‘Atypical’ refers to the cells having an irregular shape or arrangement that is not typical of normal cells.

ADH is a benign proliferative lesion, abnormal in number and shape, but not cancerous. This distinction shapes all subsequent decisions.

ADH is usually found incidentally, and patients rarely have symptoms. It often appears in pathology after biopsy for a mammographic abnormality, such as a cluster of calcifications.

How ADH Differs from Other Diagnoses

This area of pathology is often confusing. Knowing where ADH fits among related diagnoses helps clarify its significance:

• Usual ductal hyperplasia (UDH): This is when more cells than usual line the breast duct, but these cells look normal under a microscope. There is minimal change in long-term risk.
• Atypical ductal hyperplasia (ADH): More cells than usual line the breast ducts, and these cells appear abnormal under the microscope. This condition raises the risk of breast cancer.
• Ductal carcinoma in situ (DCIS): atypical cells, which are abnormal cells, fill the duct (a small tube in the breast) but have not invaded surrounding tissue. This is stage 0 breast cancer, meaning it is noninvasive and confined to its original location.
• Invasive ductal carcinoma: cancer cells have gone through the wall of a milk duct and entered nearby breast tissue.

ADH differs from both usual ductal hyperplasia (UDH) and ductal carcinoma in situ (DCIS). The distinction between ADH and low-grade DCIS can be subtle, which is one reason surgical excision is often recommended after a core needle biopsy finds ADH.

The Risk Elevation ADH Represents

ADH independently raises breast cancer risk, as shown by multiple long-term studies.

Women with ADH have approximately four to five times the breast cancer risk of women without proliferative changes. This risk applies to both breasts and is higher with a family history of breast cancer.

Over 25 years, the cumulative risk of breast cancer after ADH is around 30 percent. Even though significant, most women with ADH will not develop cancer. Surveillance and risk-reduction strategies help manage this risk.

Why Family History Changes the Equation

Having both ADH and a first-degree family history of breast cancer approximately doubles the risk compared to having ADH alone. If both are present, the medical team will usually recommend more detailed risk-reduction discussions, including chemoprevention and other preventive options tailored to the individual’s risk level.

What Happens After a Core Needle Biopsy Returns ADH

A core needle biopsy removes a small tissue sample with a hollow needle. With ADH findings, the key concern is whether the biopsy captures the full extent of the abnormality.

Research shows that a meaningful percentage of core needle biopsies returning ADH are upgraded to DCIS or invasive cancer when the area is surgically excised, and the tissue is examined in full. Upgrade rates in the published literature vary, but estimates consistently fall in the range of 15 to 30 percent, with some series reporting higher rates, depending on biopsy technique, lesion size, and imaging characteristics.

This upgrade rate is the main reason surgical excision is often recommended after a core needle biopsy reveals ADH. The excision ensures no higher-grade abnormality is present in tissue not sampled by the biopsy.

When Surgical Excision Is Recommended

Surgical excision is not automatic. The clinical team bases the decision on several related factors:

• The size and extent of the ADH on biopsy
• Whether the ADH was completely sampled or appeared to extend to the biopsy margin
• Imaging characteristics of the original lesion, including the size of the calcification cluster
• Biopsy technique matters. Vacuum-assisted biopsies sample more tissue than standard core biopsies by using suction to collect additional tissue.
• Patient risk factors, including family history and personal history

If excision is needed, Bedford Breast Center offers minimally invasive lump removal (MILR) when appropriate. MILR uses a small incision to remove the target area, preserving as much breast tissue as possible and allowing full tissue examination.

Ongoing Surveillance After ADH

Regardless of excision, ADH alters ongoing breast care. Annual mammography alone is insufficient for most.

Evidence supports more active surveillance, often including:

• Annual mammography with 3D tomosynthesis
• Annual breast MRI for patients with elevated lifetime risk
• Clinical breast exam every six to twelve months
• Risk assessment and ongoing reassessment as new information becomes available

Protocols are individualized. At Bedford Breast Center, ADH patients receive a care plan based on imaging, family history, genetic testing (if applicable), and personal risk preferences.

Risk Reduction: Understanding Your Options

For higher-risk patients, evidence-based options are available.

Chemoprevention

Selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, and aromatase inhibitors, such as exemestane and anastrozole, have been studied as risk-reduction agents in high-risk women. SERMs are medications that block estrogen in breast tissue. Aromatase inhibitors are drugs that lower estrogen levels in the body. Clinical trials have demonstrated meaningful reductions in breast cancer incidence in women with atypical lesions who take these medications.

Chemoprevention does not suit everyone; its benefits must be weighed against side effects and health history. Bedford Breast Center’s team assesses each patient before recommending treatment.

Lifestyle and Modifiable Risk Factors

While ADH itself cannot be reversed, evidence supports the role of modifiable factors in overall breast cancer risk. Routine physical activity, limiting alcohol intake, maintaining a healthy weight, and avoiding hormone replacement therapy unless clearly indicated are all associated with risk reduction. These recommendations are not a substitute for clinical monitoring but are a reasonable complement to it.

Genetic Testing and ADH

ADH is not caused by BRCA1 or BRCA2 mutations, and most women with ADH do not carry hereditary breast cancer genes. Still, ADH plus a significant family history justifies genetic counseling and testing.

Knowing if hereditary risk is present alters risk calculation and may affect family screening recommendations.

Bedford Breast Center offers genetic testing and risk evaluation as part of a coordinated care approach. Patients do not need to manage this separately.

ADH Evaluation and Management at Bedford Breast Center

Bedford Breast Center is a dedicated breast center in Beverly Hills, serving patients throughout Los Angeles, the San Fernando Valley, and Orange County, as well as nationally for those who travel for specialized breast care.

After an ADH diagnosis, the next step is consultation with a breast specialist to review pathology, imaging, and clinical details. At Bedford Breast Center, evaluations are coordinated and thorough, providing patients with clear guidance for next steps.

Bedford Breast Center is located at 436 N. Bedford Drive, Suite 103, Beverly Hills, CA 90210. Appointments can be scheduled by calling (310) 278-8590 or through the website at bedfordbreastcenter.com.

Frequently Asked Questions About Atypical Ductal Hyperplasia

Is atypical ductal hyperplasia cancer?

No. ADH is a benign finding. However, it does represent an elevated risk for developing breast cancer in the future, which is why clinical monitoring, and in some cases, further evaluation are recommended.

Will I need surgery after an ADH diagnosis?

Not always, but surgical excision is frequently recommended after a core needle biopsy returns ADH. The reason is a documented rate of upgrade to DCIS or invasive cancer when the full area is surgically removed and examined. The decision is made based on the specifics of each case.

How often should I be screened after an ADH diagnosis?

Most patients with ADH require more frequent and advanced screening than standard annual mammography. Annual MRI combined with annual mammography is common for patients with an elevated lifetime risk. Your clinical team will outline the appropriate protocol for your specific situation.

Does ADH run in families?

ADH itself is not hereditary, but breast cancer risk is. If you have ADH and a family history of breast cancer, genetic counseling may be appropriate to assess whether a genetic factor is influencing your overall risk.

What is the difference between ADH and DCIS?

ADH involves atypical cells that partially fill the breast ducts. DCIS involves atypical cells that completely fill the ducts but have not invaded surrounding tissue. DCIS is considered stage 0 breast cancer. The distinction between the two can call for careful pathologic review, and a core biopsy returning ADH can occasionally be upgraded to DCIS when the full area is surgically examined.

The post Atypical Ductal Hyperplasia: What the Diagnosis Means and What Comes Next first appeared on Bedford Breast Center.

from
https://www.bedfordbreastcenter.com/blog/atypical-ductal-hyperplasia-what-the-diagnosis-means-and-what-comes-next/?utm_source=rss&utm_medium=rss&utm_campaign=atypical-ductal-hyperplasia-what-the-diagnosis-means-and-what-comes-next